Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

commensal bacterial strain formulation BMC128

An oral formulation composed of four unique and live commensal bacterial strains that are natural inhabitants of the human intestinal tract, with potential immunostimulating and antineoplastic activities. Upon administration of the commensal bacterial strain formulation BMC128, the bacterial strains may promote intra-tumoral lymphocytic infiltration and increase the population of natural killer (NK) cells, and cytotoxic CD4+ and CD8+ T cells. This may enhance anti-tumor immune response and may eradicate tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:bacterial consortium-based formulation BMC128
LBP BMC128
live bacteria product BMC128
live biotherapeutic product BMC128
Code name:BMC 128
BMC-128
BMC128
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search